MedTrace Logo

Improved Early Diagnosis in Female Pelvic Cancer With OC Detect

NCT06613230 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 490

Last updated 2025-04-18

No results posted yet for this study

Summary

The goal of this observational study is to learn if so called Volatile Organic Compounds (VOCs) in blood can be used for early diagnosis of ovarian cancer. The main question it aims to answer is:

Can OC Detect, a new in vitro diagnostic instrument, distinguish between VOC patterns in blood plasma from women with ovarian cancer (especially in early stage) and VOC patterns in helthy women? Participants are previosuly diagnosed patients with ovarian cancer, who agreed to store their blood samples in biobanks for future medical research purposes. Healthy female blood donors serve as benign control blood samples.

Conditions

Sponsors & Collaborators

  • Linkoeping University

    collaborator OTHER_GOV

  • VOC Diagnostics

    collaborator INDUSTRY

  • Region Skane

    lead OTHER

Principal Investigators

  • Jens Eriksson, Ass Prof · Linkoeping University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06613230 on ClinicalTrials.gov